无驱动基因改变的IV期非小细胞肺癌治疗:ASCO活指南
ASCO基于2018至2021年随机临床试验的系统综述更新2020年指南,针对无驱动基因改变的IV期非小细胞肺癌提供系统治疗推荐。五项随机临床试验构成证据基础,结局指标包括疗效和安全性。推荐覆盖不同PD-L1表达水平、组织学类型和体能状态下的免疫单药、双免疫联合及化疗方案选择。
要点
- 高PD-L1表达(TPS≥50%)、非鳞癌、PS 0-1患者,临床医生可提供阿替利珠单抗单药。
- 高PD-L1表达、鳞癌、PS 0-1患者,临床医生可提供纳武利尤单抗联合伊匹木单抗单用或联合两个周期铂类化疗。
- 非鳞癌一线接受免疫检查点抑制剂联合化疗后,二线可提供紫杉醇联合贝伐珠单抗。
核心结论
- 本指南更新反映了自上次更新以来的证据变化,基于五项随机临床试验提供推荐。
研究设计与样本
- ASCO基于2018年至2021年随机临床试验的持续系统综述更新推荐。
- 五项随机临床试验提供证据基础,结局指标包括疗效和安全性。
主要发现
- 五项随机临床试验构成证据基础,结局指标包括疗效和安全性。
关键数值与推荐
- 高PD-L1表达(TPS≥50%)、非鳞癌、PS 0-1:除2020年选项外,临床医生可提供阿替利珠单抗单药。
- 高PD-L1表达(TPS≥50%)、非鳞癌、PS 0-1:临床医生可提供纳武利尤单抗联合伊匹木单抗单用或联合化疗。
- PD-L1阴性(0%)和低阳性(TPS 1%-49%)、非鳞癌、PS 0-1:临床医生可提供纳武利尤单抗联合伊匹木单抗单用或联合化疗。
- 高PD-L1表达、鳞癌、PS 0-1:临床医生可提供阿替利珠单抗单药,或纳武利尤单抗联合伊匹木单抗单用或联合两个周期铂类化疗。
- PD-L1阴性和低阳性、鳞癌、PS 0-1:临床医生可提供纳武利尤单抗联合伊匹木单抗单用或联合两个周期铂类化疗。
临床怎么用
- 非鳞癌患者一线接受免疫检查点抑制剂联合化疗后,临床医生可提供二线紫杉醇联合贝伐珠单抗。
- 非鳞癌患者接受化疗联合或不联合贝伐珠单抗及免疫检查点抑制剂治疗后,临床医生应提供三线单药培美曲塞、多西他赛或紫杉醇联合贝伐珠单抗的选项。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non-small-cell lung cancer without driver alterations. METHODS: ASCO updated recommendations on the basis of an ongoing systematic review of randomized clinical trials from 2018 to 2021. RESULTS: This guideline update reflects changes in evidence since the previous update. Five randomized clinical trials provide the evidence base. Outcomes of interest include efficacy and safety. RECOMMENDATIONS: In addition to 2020 options for patients with high programmed death ligand-1 (PD-L1) expression (tumor proportion score [TPS] ≥ 50%), nonsquamous cell carcinoma (non-SCC), and performance status (PS) 0-1, clinicians may offer single-agent atezolizumab. With high PD-L1 expression (TPS ≥ 50%), non-SCC, and PS 0-1, clinicians may offer nivolumab and ipilumumab alone or nivolumab and ipilimumab plus chemotherapy. With negative (0%) and low positive PD-L1 expression (TPS 1%-49%), non-SCC, and PS 0-1, clinicians may offer nivolumab and ipilimumab alone or nivolumab and ipilimumab plus chemotherapy. With high PD-L1 expression, SCC, and PS 0-1, clinicians may offer single-agent atezolizumab. With high PD-L1 expression, squamous cell carcinoma (SCC), and PS 0-1, clinicians may offer nivolumab and ipilimumab alone or in combination with two cycles of platinum-based chemotherapy. With negative and low positive PD-L1 expression, SCC, and PS 0-1, clinicians may offer nivolumab and ipilimumab alone or in combination with two cycles of platinum-based chemotherapy. With non-SCC who received an immune checkpoint inhibitor and chemotherapy as first-line therapy, clinicians may offer second-line paclitaxel plus bevacizumab. With non-SCC, who received chemotherapy with or without bevacizumab and immune checkpoint inhibitor therapy, clinicians should offer the options of third-line single-agent pemetrexed, docetaxel, or paclitaxel plus bevacizumab.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
引用
- Singh N, Temin S, Baker S, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. J Clin Oncol. 2022. PMID: 35816668. doi:10.1200/JCO.22.00825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。